Welcome to our dedicated page for NewcelX news (Ticker: NCEL), a resource for investors and traders seeking the latest updates and insights on NewcelX stock.
NewcelX Ltd. (Nasdaq: NCEL) is a Zurich-based clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The NewcelX news feed on Stock Titan highlights company announcements that shed light on its ALS, Type 1 Diabetes, and CNS-focused programs, as well as its broader strategy in regenerative medicine and neuroscience.
Investors and observers can follow updates on AstroRx®, NewcelX’s cell-therapy program for ALS, and IsletRx, its stem-cell–derived islet therapy for insulin-dependent Type 1 Diabetes. News items include results from international collaborative studies on biomaterial approaches for stem-cell–derived islet delivery, which explore engineered scaffolds and extracellular matrix integration to support islet function and potentially reduce the need for chronic immunosuppression.
The news stream also covers developments in the DOXA small-molecule platform, such as publication of patent applications in key markets like China for quinazoline, benzothiazine, and benzoxazine derivatives targeting neurological diseases. These updates provide insight into how NewcelX is expanding its intellectual property footprint and advancing CNS drug discovery linked to sleep-wake regulation, orexin signaling, and metabolic control.
Additional coverage features scientific and strategic appointments to the company’s Scientific Advisory Board, reflecting expertise in diabetes innovation, ALS, neuroimmunology, and stem-cell-based regenerative medicine. Corporate communications, including shareholder letters and roadmap updates following the merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd., offer context on NewcelX’s integrated platform, clinical plans, and financial positioning. For readers tracking NCEL, this news page brings together scientific, clinical, intellectual property, and governance milestones in one place.
NewcelX (Nasdaq: NCEL) announced on November 3, 2025 that it has posted an investor presentation on its website. The company is a Swiss clinical-stage biopharmaceutical developer of cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, combining regenerative medicine and neuroscience expertise within a unified platform.
The investor presentation slides are available via the Corporate Presentation page in the Investor Relations & Media section at https://newcelx.com/investors-media/investors/corporate-presentation/.